Skip to main content
HYUNDAI PHARMACEUTICAL CO., LTD logo

HYUNDAI PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 004310 ISIN · KR7004310009 KO Manufacturing
Open in API
Filings indexed 184 across all filing types
Latest filing 2026-02-09 Notice of Dividend Amou…
Country KR South Korea
Listing KO 004310

About HYUNDAI PHARMACEUTICAL CO., LTD

http://www.hyundaipharm.co.kr/english

HYUNDAI PHARMACEUTICAL CO., LTD. is a company engaged in the research, development, manufacturing, and distribution of pharmaceutical products, medical devices, and health-focused food and beverages. The company's portfolio encompasses a broad range of prescription (ETC) and over-the-counter (OTC) medicines. Key therapeutic areas include dermatology, respiratory and gastrointestinal disorders, as well as treatments for conditions such as hypertension and dementia. With a strong commitment to innovation, the company focuses on the research of new substances and the continuous development of its drug pipeline. It also serves as a strategic partner for global companies, facilitating market entry and collaboration through its business development initiatives.

Recent filings

Filing Released Lang Actions
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is an official announcement from Hyundai Pharm regarding a decision on cash dividends. It specifies the dividend amount per share, the dividend yield, the total dividend amount, the record date, and the date of the general meeting of shareholders. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2026-02-09 Korean
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
Notice of Dividend Amount Classification · 98% confidence The document is a regulatory filing from Hyundai Pharm regarding the determination of a record date for shareholder registry closure for the purpose of cash/in-kind dividends. It specifies the record date (2026-03-04) and the purpose (confirming shareholders for dividends). Since this is a formal regulatory announcement regarding dividend-related procedures rather than the dividend amount itself or a general report, it falls under the category of regulatory filings.
2026-02-09 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Management Reports Classification · 95% confidence The document is a regulatory filing from Hyundai Pharm regarding a significant change in sales or profit structure (30% or more). It provides preliminary financial results (revenue, operating profit, net income) for the fiscal year ending 2025-11-30 compared to the previous year. This type of disclosure is a standard preliminary earnings announcement in the Korean market (DART system), which falls under the 'Earnings Release' category as it provides key financial highlights before the final audited report is published.
2026-01-05 Korean
분기보고서 (2025.08)
Interim / Quarterly Report Classification · 100% confidence The document is titled '분기보고서' which translates to 'Quarterly Report' and specifies the period from December 1, 2024 to August 31, 2025, indicating it covers a partial fiscal year. The content includes detailed financial statements, business overview, management analysis, and auditor's opinion sections typical of an interim or quarterly report. The length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2025
2025-10-15 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the approval of a new drug product by the Korean Ministry of Food and Drug Safety (MFDS). It includes details about the product, approval dates, and regulatory body. The document length is only 1257 characters, indicating it is a brief announcement rather than a full report. There is no financial data, no detailed management discussion, or comprehensive report content. It is an investment judgment related important management matter announcement, typical of regulatory filings for material corporate events. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-09-29 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 100% confidence The document is a regulatory disclosure from Hyundai Pharm regarding the approval of a Phase 3 clinical trial by the MFDS (Ministry of Food and Drug Safety). It details the clinical trial design, objectives, and regulatory status. Since this is a specific regulatory announcement regarding business operations (clinical trial approval) that does not fit into financial reporting, dividend, or governance categories, it is classified as a general regulatory filing.
2025-07-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.